| Literature DB >> 33242508 |
Caroline Bleakley1, Suveer Singh2, Benjamin Garfield2, Marco Morosin2, Elena Surkova3, Ms Sundhiya Mandalia4, Bernardo Dias3, Emmanouil Androulakis5, Laura C Price6, Colm McCabe6, Stephen John Wort6, Cathy West3, Wei Li7, Rajdeep Khattar7, Roxy Senior7, Brijesh V Patel2, Susanna Price8.
Abstract
AIMS: Comprehensive echocardiography assessment of right ventricular (RV) impairment has not been reported in critically ill patients with COVID-19. We detail the specific phenotype and clinical associations of RV impairment in COVID-19 acute respiratory distress syndrome (ARDS).Entities:
Keywords: Acute respiratory distress syndrome; COVID-19; Critical care; Echocardiography; Right ventricle
Mesh:
Year: 2020 PMID: 33242508 PMCID: PMC7681038 DOI: 10.1016/j.ijcard.2020.11.043
Source DB: PubMed Journal: Int J Cardiol ISSN: 0167-5273 Impact factor: 4.164
Demographics of 90 consecutive patients diagnosed with COVID-19 on the Intensive Care Unit at the Royal Brompton Hospital who underwent echocardiography. Ethnicity (1 = Caucasian, 2 = Asian, 3 = black). Body surface area (BSA), Body mass index (BMI), Hypertension (HTN), Diabetes (DM), Chronic obstructive pulmonary disease (COPD), chronic kidney disease (CKD), Angiotensin converting enzyme inhibitor (ACEi) angiotensin receptor blocker (ARB), Brain natriuretic peptide (BNP), Positive end expiratory pressure (PEEP), Alanine aminotransferase (ALT), high sensitivity C-reactive protein (hsCRP), (hs-TnI) high-sensitivity troponin I, (eGFR) estimated glomerular filtration rate.
| Mean (sd) /Median (IQR) / n (%) | Total n | ||
|---|---|---|---|
| Age | 52.0 (10.8) | 90 | |
| Sex | Male | 67 (74.4) | 90 |
| Ethnicity | 1 | 38 (42.2) | 88 |
| 2 | 42 (46.7) | ||
| 3 | 8 (8.9) | ||
| BSA, m2 | 2.0 (0.2) | 86 | |
| BMI, kg/m2 | 29. 5 (6.6) | 85 | |
| VVECMO (n) | 38 (42.2%) | 90 | |
| Medical history | |||
| HTN | 33 (36.7%) | 87 | |
| DM | 20 (22.2%) | 87 | |
| COPD | 1 (1.1%) | 87 | |
| CKD | 2 (2.2%) | 87 | |
| ACEi/ARB use | 21 (23.3%) | 84 | |
| Drug therapy | |||
| Steroids | 44 (48.9%) | 87 | |
| Inotropes | 19 (21.1%) | 87 | |
| Vasopressors | 84 (93.3%) | 87 | |
| Ventilatory | |||
| PaO2:FiO2 ratio | 22.3 (10.1) | 87 | |
| PEEP | 11.2 (2.5) | 85 | |
| Murray Score | 3(2.8–3.3) | 87 | |
| Laboratory measures | |||
| ALT | 45 (29–61) | 87 | |
| D-dimer | 3285(2162–8663) | 84 | |
| hsCRP | 266.8 (114.2) | 87 | |
| Highest BNP | 100 (52–226) | 78 | |
| hs-TnI | 169.6 (630.8) | 86 | |
| eGFR | 92.7 (68.6) | 86 |
Mean and standard deviation of measures of right heart function in critically unwell patients with COVID-19 who underwent echocardiography along with normal values and total number of patients having each measurement taken. Right ventricle fractional area change (RV FAC), Right ventricle velocity time integral (RV VTI), Tricuspid annular plane systolic excursion (TAPSE), Right ventricular S velocity (RVS’), Right ventricle free wall strain (RVFWS).
| Normal value | Mean(sd) | Total n | |
|---|---|---|---|
| LVEF(%) | ≥52 female | 59.91(10.98) | 80 |
| LVOT VTI (cm) | >18 | 20.2 (5.2) | 83 |
| E/e’ | <14 | 8.9 (2.2) | 83 |
| RVEDA (cm2) | 10–24 | 22.6(5.5) | 76 |
| RVEDAi (cm2/m2) | 5–12.6 | 11.3(2.6) | 76 |
| RVESA (cm2) | 3–15 | 16.3(5.5) | 76 |
| RVESAi (cm2/m2) | 2–7.4 | 8.2(2.6) | 76 |
| RV FAC, % | ≥ 35 | 28.9(10.6) | 75 |
| RV VTI, cm | ≥ 19 | 14.3(4.2) | 81 |
| TAPSE, mm | ≥ 17 | 20.0(4.8) | 84 |
| RVS’ (cm/s) | ≥ 9.5 | 13.5(3.8) | 84 |
| RV free wall strain (%) | ≥ −22 | −24.1(6.9) | 51 |
| RVSP (mmHg) | <25 | 46.8(14.9) | 65 |
| PVR (WU) | <1.6 | 2.3(0.9) | 65 |
Fig. 1Proportion of patients with COVID-19 admitted to critical care identified as having abnormal right ventricular function defined by different measures. The tricuspid annular plane systolic excursion (TAPSE) defined 23.8 (95 CI 16.0–33.9) % as having RV dysfunction and 76.2 (95% CI 66.1–84.0) % as having normal RV function. Right ventricular velocity time integral (RV VTI) defined 86.4 (95 CI 77.3–93.2) % as having RV dysfunction and 13.6 (95% CI 7.8–22.7)% as having normal RV function. Right ventricular systolic velocity (RVS’) defined 11.9 (95% CI 6.6–20.5) % as having RV dysfunction and 88.1 (95% CI 79.4–93.4)% as having normal RV function. Right ventricular fractional area change (RV FAC) defined 72.0 (95% CI 61.0–81.0) % as having RV dysfunction and 28.0 (95% CI 19.0–39.0)% as having normal RV function. Right ventricular free wall strain (RVFWS) defined 35.3 (95% CI 23.6–49.0) % as having RV dysfunction and 64.7 (95% CI 51.0–76.4) % as having normal RV function. Chi squared 164.7, df 4, p < 0.001.
Fig. 2Significant correlations of measures of right ventricular function and right ventricular size in critically unwell patients with COVID-19. A) Right ventricular fractional area change (RV FAC) is plotted against right ventricular end diastolic area index (REVDAI) and B) against indexed right ventricular end systolic area (RVESAi). C) Right ventricular velocity time integral (RV VTI) is plotted against RVEDAi and D) against RVESAi. E) Tricuspid annular plane systolic excursion (TAPSE) is plotted against RVESAi.
Fig. 3Significant correlations between right ventricular fractional area change (RV FAC) and other measures of right ventricular function in critically unwell COVID-19 patients. A) RV FAC plotted against right ventricular velocity time integral (RV VTI). B) RV FAC plotted against tricuspid annular plane systolic excursion (TAPSE). C) RV FAC plotted against right ventricular S velocity (RVS’).
Univariate regression of right ventricular fractional area change (RV FAC) against baseline biochemical, ventilatory, inflammatory markers as well as echocardiographic measures of pulmonary hypertension in critically unwell patients with COVID-19. Brain natriuretic peptide (BNP), right ventricular systolic pressure (RVSP), pulmonary vascular resistance (PVR), positive end expiratory pressure (PEEP), alanine aminotransfersase (ALT), high sensitivity C-reactive protein (CRP).
| Correlations with RV FAC | Gradient (intercept) | p-value |
|---|---|---|
| NTpro-BNP | −0.01 (29.6) | 0.009 |
| RVSP | −0.03 (29.9) | 0.726 |
| PVR | −5.2 (41.0) | <0.001 |
| PaO2:FiO2 ratio | 0.2 (25.5) | 0.222 |
| PEEP | −0.04 (29.7) | 0.928 |
| ALT | −0.05 (31.8) | 0.098 |
| D-dimer | −0.00004 (29.1) | 0.769 |
| hsCRP | 0.02 (24.7) | 0.162 |
| TnI | −3.68 (34.34) | 0.039 |
Fig. 4Significant correlations of right ventricular size and pulmonary vascular resistance with right ventricular-pulmonary artery coupling measured by right ventricular fractional area change (RV FAC) / Right ventricular systolic pressure (RVSP) in critically unwell patients with COVID-19. A) RV FAC/RVSP plotted against indexed right ventricular end diastolic area (RVEDAi). B) RV FAC/RVSP plotted against indexed right ventricular end systolic area (RVESAi). C) RV FAC/RVSP plotted against pulmonary vascular resistance (PVR).
Univariate regression of right ventricular fractional area change (RV FAC) / right ventricular systolic pressure (RVSP) against baseline biochemical, ventilatory, inflammatory markers in critically unwell patients with COVID-19. NTpro-Brain naturiretic peptide (BNP), positive end expiratory pressure (PEEP), Alanine aminotransfersase (ALT), high sensitivity C-reactive protein (CRP).
| Correlations with RV FAC / RVSP | Gradient (intercept) | p-value |
|---|---|---|
| NTpro-BNP | 397.2 (−264.1) | 0.056 |
| PaO2:FiO2 ratio | 15.41 (8.99) | 0.026 |
| PEEP | 12.27 (−2.03) | 0.025 |
| ALT | 74.01 (−32.83) | 0.028 |
| D-dimer | 9448 (−2876) | 0.49 |
| hsCRP | 248.5 (40.96) | 0.35 |
| TnI | 128.7 (135) | 0.64 |